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Disturbances of Blooil Clotting Mechanism
Iniluceil bv Antimetabolites of Vitamin K
H. C. Hnlmnn, J. vAN DER Mnnn, R,. Hoocn and E. A. Lonr,rcnn
Laboratory for Coagulation and Cardiovascular Biochemistry,
Dept. of Internal Medicine, University Hospital, Leyden
There is ample evidence that the coumarol and phenylandion drugs act by
competition with vitamin K (28). Intake of these drugs thus leads to a relative
vitamin K deficiency.
It is therefore impossible to discuss the mode of action of these drugs without
discussing the mode of action of vitamin K. As the foregoing review of PnNrocr
(46) already corrers this subject some of the information presented in this
communication is already familiar to you. I hope to demonstrate that the
biochemistry of human pathology leads to essentially the same conclusions as
does the general biochemistry reviewed by Pnnlvocr<. I think his presentation
and the present one will be supplementary because the postulate on the site of
action of a vitamin K antagonist that will be presented here is essentially a
postulate on the mode of action of vitamin K.
Because the methodology in coagulation biochemistry is still a cause of
many conflicting reports, we will have to include a heading materials and
methods. After that we will discuss the behaviour of the clotting factors after
intake of coumatol congeners. Then we will report on the blood coagulation
inhibiting protein present in vitamin K deficiency, and discuss its fundamental
and clinical importance. X'inally we will show how the coagulation factors react
to the administration of vitamin K during Marcoumar intake.
Materials anil Methotls
The studies reported here have mostly been carried out on blood samples of
not severely ill, ambulant patients that were receiving anticoagulant treatment
by administration of Marcoumar (phenprocoumon; 3-(1-phenylpropyl)-4-
hydroxycoumarin) or of volunteers that received the same drug. Only where
indicated below, plasma from patients with an absolute vitamin K deficiency
or other important concomitant illness was used.
The methodology of coagulation factor determination is most important in
this kind of investigations. All coagulation factors have been estimated in
specific one stage tests. The reaction mixture consisted of:0.7mlreagent,i.e. a
plasma containing all coagulant factors in approximately normal amounts
except the factor that had to be determined; 0.1m1, thrombopl,astin;0.7m1'
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sanq)le;0.1m| cactz 25mM. The clotting time obtained wjth a sample of
orrk-rro*n clotting-factor content in such a system was related to the coagula-
tion-factor concentration in that sample by comparison with a standard curve
obtained with dilutions of normal plasma. The reagents and thromboplastins
were: Factor II assay: Artificially factor II deficient plasma prepared according
toLonr,rcnR(26)orcongenital lyfactor l ldef ic ientplasma;thromboplast in
accord.ing to Ownnw and Aas (43). Iactor VII and' X assay: R'eagent prepa'r-
"d 
ac"ordi.rg to Bacnn,o.n (3) ; thromboplastin according to ownnw and Aas'
X'actor V assay: reagent according to Kann (21); thromboplastin according to
ownnu and Aes. Factor vII or x assay : congenitally factor YTI or X deficient
plasma as a reagent; thromboplastin according to ownnN and Aes. Iactor x
Zrroy, reagent as in factor VII and X assay; thromboplastin: phospholipid
*o.p""rr.ion according to Mrr,sroNn (a0) containing Russnr,r,s viper venom/mI'
Iactor IX assay: according to vnr,rxeur (56). Thrombotest assa,y: (4+, +5)
o.25 mlthrombotest reagenilNvncaenn) 0.05 ml plasma sample. The standard
error of the results varied between 3 and 5o/o'
Reaction of the Bloott clotting Factors to Ailministration of coumarol congeners
vitamin K is mandatory for the biosynthesis of the coagulation factors II
(g, 52),VII (23, 4g, 48), fXlSOl and X (22), intake of coumarol congeners leads
to a red.uction or termination of the synthesis of these factors. severe reduction
of the level of these factors in the plasma causes a hemorrhagic diathesis' The
degree of hemorrhagic diathesis depends upon the level of the.clotting factors'
Joit u. in hemophilia it can be qualified as mild (5-250/; moderate (t-1o/) ot
seYere (0-1%)'
It has been proven that the coagulation factors under discussion are plasma
glycoproteins that are synthesized in the liver (1, 4). The few reports indicating
that these f'actors are also synthesized outside the liver i.e. in the bone maruow,
are obviousiy mistaken (19;57). Coumarol congeners thus inhibit the synthesis
of certain specific glycoproteins in the liver'
Intake of a sufhciently large dose of Matcoumar blocks the synthesis
completely. The factors then disappea,I.from the blood with a velocity that is
determined by a constant specific for each ciotting factor and by the concentra-
tion of this clotting factor. The level of the clotting factors thus will show an
exponential decay, as indicated in fig' 1'
The reaction constant of this decay is most easily expressed as its biological
half life time (B.II.T.), i.e. the time that is necessary for a given concentration
of the clotting factor in plasma to reach half its original value. This B.H'T' is
essentially in[ependent of ttie way in which the synthesis is blocked. Its value
is the same in liver destruction due to poison, genetically determined inability
to synthesize or blockade by absence of functional vitamin K (18, 24). The
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Fig. 1. schematic view of the disappearance of the vitamin I{ dependent coagulation
fa&ors from the blood after intake of large doses of a coumarin congeners. The factors
disappear from tho blood with a velocity determined by their half-life time.
biological half life times of different clotting factors are illustrated in table 1.
X'rom this table it is directly clear that there is no connection between turnover
rate of a coa,gulation factor and its vitamin K dependancy. This is an important
point to keep in mjnd for the discussion of MA-Rrrus'theory on the mode of
action of vitamin K. With high and maintained doses of Marcoumar the clotting
factors II, VII, IX and x will eventually disappear from the blood.
when Marcoumar is administered in daily doses that do not completely
block the synthesis a steady state of anticoagulation will be reached in which
all four coagulation factors involved ale decreased to the same level (25,27).
Table 1. Biological half-life time of coagulation factors.
Factor Namo B.H.T.  (h ) Vit. It Dep.
I
II
v
\rII
VIII
IX
x
xII
fibrinogen
prothrombin
accellerin
convertin
A.H,F . .A
A.H.F . .B
Stuart-Prower F.
Ilageman F.
109 + 13
60
5-10
6
l4
20
40
60
1
-T-
+
+
201
o
o.
u)
I
.3 too
F
o
o
o
6 5 0
o
o
25
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This fact has hitherto not been firmly established. Conflicting reports exist
as to the levels of clotting factors existing in steady-state long term anti-
coagulant treatment (53). In our opinion this is partly due to insufficiently
standardized techniques, partly to the influence of an inhibitor occurring in
vitamin K deficiency. The nature and influence of this inhibitor will be dis-
cussed below.
rt can be seen from table 2 that independent of the level of steady-state
anticoagulation that is reached, there is no significant difference between the
four vitamin K dependent coagulation factors. on the other hand it can be
observed that a distinctly different coagulation factor concentration is found
Table 2. Concentration of coagulation factors at, different levels of anticoagulant treat-
ment.
Subjects Anti-coagulation
Levels of coagulation clottine factors Throm-
botest(%)
Discre-
pancyil VII IX X MEAN V
Normals
Coronary
infarction
Coronary
infarction
vit.-K-
deficiency
Liver disease
Mild
Deep
Moderately
Deep
None
None
rs.7
t2 .5
1 5 . 8
36.9
34.5
20.4
1 3 . 8
14.9
p8.7
37.4
22.6
12.0
r6.2
30.8
34.4
20.6
12.0
14.3
.to. o
39.7
20.8
12.6
15.3
35.5
36.5
103
97
105
1 1 6
47
L2.O
7 .3
8.2
24.0
o  i . D
+
+
+
+
E 2 0
o
o
o
b 1 5
E
z
0 1 2 3 4 5 6 7 8 9 1 0
Mean daily dose of Marcoumar (mg)
Fig' 2' Frepuention-distribution diagram of the mean daily dose of Marcoumar necessary
to obtain a coagulation factor level of I5o/o, Calculated for 100 patients over a 150 days'
period.
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when a different a,ssa,y method (rThrombotest<) is used. The cause of this
discrepancy between different methods will be explained later. X'rom table 2 it
can be seen to occur only in cases of relative or absolute vitamin K deficiency
and not when the factors are lowered as a cause of parenchymatous liver
disease.
Thrombotest activity (o/o, log.scale )
200 Batch nr.226
150
4 5 6] 10 20 100
Thrombotest activity ("/")
Fig. 3. Two different ways of plotting clotting time as a function of plasma dilution in a
Thrombotest oxperiment. The rectilinearity of the plot of the inverse of the concentration
against clotting time is evident.
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G
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An unchanging level of a coagulation factor in the blood means that the
rate of production equals the rate of decay. When the level of all four coagula-
tion factors comes down to the same percentage of the norma,l level, this means
that the velocity of synthesis is inhibited to the same extent for all four of these
factors. The same amount of Marcoumar thus affects the four synthesis
mechanisms in one individual in the same way. There is a rather broad indivi-
dual variation in the dose response relationship of coumarin congeners. This is
indicated in fig. 2 which gives the frequency distribution of the mean daily dose
that is necess&ry to reach a steady level of 15 o/o of the factors II, VII, IX and X.
Although heriditary resistance to antimetabolites of vitamin K has been
described in men as well as in rats (46, 59), such cases were neYer observed in
the practice of our Thrombosis service. Roughly estimated 10000 patients fell
within the more or less normal distribution depicted in fig. 2.
The Circulating Anticoagulant Occurring in Yitamin K Deficiency
It has been proven that a plot ofthe inverse of coagulation factor concentra-
tion against clotting time in a Thrombotest assay is a straight line (fig. 3) (15).
It has also been proyen that the clotting factor that is rate-limiting in this
assay is factor X (15). This allows us to calculate by extrapolation the clotting
time that would be observed at an infinite concentration of factor X. The time
thus computed has to be the same when calculated from the values obtained
with different plasmas that are deficient in factor X to different degrees,
because once the extrapolation to infinite factor X concentration has been
Hepatitis
(n=7;  f  :35t1,5%)
Normal
(n = 30;pooled;f :10032%)
% D 4
Fig. 4. The clotting-time - dilution graph in chronic hepatitis (from ref. 14).
%%
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carried out, the values from which the extrapolation has been effected are no
longer of importance.
X'ig. 4 shows a representative experiment in which a pooled plasma of
patients with parenchymatous liver disease is demonstrated to have the same
minimal clotting time as normal plasma has, thus behaving as one would
expect.
When we do the same experiment with plasma from a patient with absolute
or relative vitamin K deficiency however, we find that extrapolation to infinite
clotting factor concentration gives clotting times that are distinctly higher than
was to be expected (fig.S).
We have been able to show that this is due to the fact that in vitamin K
deficiency a, circulating anticoagulant occurs that acts as a competitive
inhibitor of the coagulation reaction. This inhibitor we called P I V KA.. Protein
Induced by Vitamin K Absence (14, 16).
Elementary mathematics show (13) that in the case of a competitive
inhibitor diluted along with the substrate-which is essentially the case we &re
dealing with-the amount of inhibitor is rendered as the length of the horizontal
line dotted in fig. 5.
Fig; 5a. The clotting time - dilution graph vitamin I( defi.ciency.
T (sec)
Vit. K deficiency
(n =4; f :3211;8o/o)
(n=30.pooled;f :1O012%)
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T (sec)
Coumarin treament(n=6;f :38t1,7%)
D4
Fig. 5b. The clotting time dilution graph in coumarin treatmont. The dotted horizontal
line is called I, it is a measure of the amount of inhibitor present (frorn ref. 14).
This provides us with a me&ns of estimating theinhibitor. The concentration
is expressed in Units, one unit being the amount that causes a length of I equal
to the unit of length of the X-axis. Table 3 shows that PIVKA is a high mole-
cular, heat labile substance with absorption properties much like the clotting
Level of clotting factors (/o)
Pivka (U)
A
B
C
D
E
F
G
H
I
K
Normal
Marcoumar
A-adsorbedl)
B-adsorbedl)
A+D
B+D
B after hoatings)
B dialysed3)
Serum of B
A + I
Adsorption with A(OH)a 2.5 rnglrnl.
4hours al 45"C,
24 hours aL 4"C.
0
1 ,5
0
0
0
0.8
0.1
t . t
0
0 .1
100
1 6
0
0
52
I
I
l 5
150
t20
100
1 8
0
0
54
8
1 2
l4
t20
tt5
100
fi5
80
100
100
100
2
72
T
48
100
15
0
0
45
n
10
15
2
60
1
2
3
Table 3. Occurrence of PIVI{A in different plasmas
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factors II, VII, IX, and X. We have not yet been able to get this inhibitor in a
purified form. Preliminary experiments indicate that separation on TEAE
columns is possible, but at an extremely low yield.
'We 
were able to localise the site of action of PIVKA at the level of factor X
(table 4, fi1. 6,7, 8, 9). The data of table 4 are already very suggestive of this.
Table 4. Specific clotting factor estimations in severely vit. K-deficient patients
Reagent Pat. B
I I L 1 /10 r l l  1 /10
Factor II cong.
Factor II art.
Fact, V art.
Factor VIf/X art.
Factor VIf cong.
Factor X acquirod def.
Factor X cong.
37 40
38 56
16  19
158 r23
73 87
84 51
71 55
46
89
195
I49
106
46
50
Patient R: Attempted suicide by prolonged intake of Sintrom
Slope t-D cltrve': to/6. Inhibitor: 1.8 U.
Patient B: Bile obstruction by carcinoma of the stomach
Slope t-D crne: 2o/o. Inhibitor: 2.0 U.
The figures give tho means of ten clotting time estimations expressed in seconds.
Fig. 6. The clotting time - clotting factor concontration relationship in a Factor X assay.
upper curve: in prosence of PWKA.
lower curve: in absence of PIVI{A.
The inverse of the clotting factor concentration is plotted along the abcissa (from ref. 1 1 ).
o
o
I
o
E
'li=
o
42
46
t 5
200
96
95
76
45
65
19
1 1 0
104
47
55
1/faktor X (%)
tltFf/iF
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Fig. ?. The clotting time-clotting-fact:i 
":::::i*iitn 
relationship in a Factor VII assav'
ffJ;"" 
""H;' il $:::::T'"iiltrTho inverse of the clotting factor concentration is plotted along the abcissa (from ref' 1 1 ) '
0 5 1 0 1 5 2 0 2 5 3 0
1 /factor V (o/o)
Fig. 8. The clotting time -1t_{!i3 111t:::::^"-""t"ation relationship in a FactonY 
assav'
['J"X" ;ffi; il ffi::Xi:"J'"?J'tr
The inverse of the clotting factor concentration is plotted along the abcissa (from ref' 11)'
(t
oq
c'
E
CD
c
o
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50
40
30
20
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1 /factor ll (o/.)
Fig. 9. The clotting time - clotting factor concentration relationspip in a Factor II assay
white dots: in absence of PIVKA.black dots : 
iilffiTi ii 
PrvKA'
When plasma low in coagulation factors but highinPlVKAis tested in different
specific assays, a clotting lime longer than the buffer time is obtained when
factor X plays a r6le in the estimation. The figures 6-9 show explicitely that
marked competitive inhibition occurs only in factor X deficiency (11).
Competitive inhibition always suggests a substrate analogue and thus a
molecule that has many properties in common with the molecule that is the
substrate of the reaction inhibited. PIVKA thus would be a molecule very
much alike factor X. We think that the action of PIVKA in the coagulation
system is sufficiently explained by the assumption that it can take the place of
factor X in coagulation reactions but then combines to form an inactive pro-
thrombinase instead of an active one.
On basis of the most recent scheme of blood coagulation (12) the action of
PMA is depicted in fig. 10. Recognition of this action provides a solution for
many of the methodological questions occurring in the control of anticoagulant
therapy.
The action of PIVKA in a coagulation system thus being largely solved, we
are left with the problem of why PIVKA occurs. This problem led us to postu-
late the polypeptide precursor theory (17) as an explanation of the action of
vitamin K in the synthesis of coagulation factors.
This theory however is better discussed against the background of other
theories on vitamin K action.
40
2 n
20
2t0 Ilemker, Meer, Ilodge, Loeliger' Dist'urbances
Normal coagulation
vi l^
y-\ lX^
X.+)/ + Ph.l ip. + a1-. 3 
Prothrombinase
Prothrombin
Prothrombinase Thrombin
Coagulation inhibited bY PIVKA
PIVKA 
vl lu 
> PIVKA'
pIVKA'* V + Ph.lip. + Ca ++ 4 lnactive "prothrombinase"
Fig. 10. Reaction scheme of the action of PIVITA as a coagulation 
inhibitor'
TheR6leofVitaminKintheSynthesisofCoagulationFactors
x,ourhypotheseshavebeenpost,ulat,edtoexplaintheact,ionofvitaminKin
the synthesis of blood clotting fact'ots u'iz'
a; Vitamin K forms part of the coagula-bion factor molecule (9)'
b) vitamin K is an issential part of the respiratory chain -phosphorylation'
Coagulation factor *y,ttf'"'i* is extremely :"1:iti:,to 
a slight decrease in
oxid."ative phosphoryIation (30 up to and-including 38)'
c) vitamin K acts at the tevet or genetic controi. It causes the synthesis of
n-RNA, carrying the information necessary for the synthesis of 
fact'ors II' VII'
IX,andX,byderepressingt 'heoperato"t t tutcontrolst 'hestructuralgenes
specific for these factors (42)'
d)VitaminKact,sbyconvert,ingpotypeptideprecursorsintofunctionalclotting
""?"J*.il1; K has been shown not to be a constituenr_9! preparations con-
t a i n i n g a h i g h s p e c i f i c a c t i v i t y o f t h e f a c t o r s l l ' V I I ' I X ; h d X ' t h e f i r s t
hypotf,esis can be directly disregarded (50' 51)'
Thesecondtypotf'"'"t,first"proposedbyMart'iuslooksat'tractive'because
it directly assigns a vital r61e to vitamin t< itt ' very important' 
biochemical
process. On first view the theory seems to be supported by 
the fact that
dicumarolactsasanuncoupler(33)ofoxidat,ivephosphorytation.Acloserlook
at the problem, however, tho** various arguments which makes 
this theory
very imProbable indeed'
a)VitaminKhasalmostcertainlybeenprovennot, to-be.aconst i tuentofthe
respiratory chain, ,ro" ,o play a rOtL in tnelechanism of oxidativ6 
phosphoryla-
tion in m&mmals, as has'beln extensively discussed by PnNNocx 
(46).
b) Dicumarol has been shown to uncoupll ail three phosphorylating sites in the
respiratory chain at the same time and to about the same ext'ent' 
even those
s i tes inwh ich i t i s imposs ib le toc la imar6 le fo rv i taminK(6 ,8) .
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c) The concentration at which dicumarol optimally uncouples is around
10-3 M, whereas a concentra,tion of 10-5 M already can have an optimal anti-
coagulating effect.
d) There is no reason why coagulation factor synthesis should be especially
sensitive to a decrease of phosphorylation. Martius states that the coagulation
factors are so sensitive, due to their extremely high turn-over rates (31)' The
turn-over rates of non-K dependent clotting factors sometimes greatly exceed
that of the vitamin K dependent ones however. n'actor V for instance, which
is not sensitive to vitamin K, has an appreciably higher turn-over than factorll
has. This can be judged from its B.II.T. which is between 5 and 10 hours,
whereas the B.H.T. of prothrombin is 60 hours. Moreover, it has been shown
above that the degree of inhibition of coagulation factor synthesis is indepen-
dent of the half life time, and therefore of the turn-over rate of a coagulation
factor (table 1).
e) We have never been able to demonstrate that dinitrophenols, known to be
potent uncouplers of oxidative phosphorylation, specifically influence coagula-
tion factor synthesis.
f) Patients with dicumarol poisoning never show the signs and symptoms
specific of poisoning with uncoupling agents.
The evidence conflicting with an action of vitamin K via the respiratory
chain phosphorylation thus seems overwhelming.
As has been shown in the review of Pnlqlrocx, it must be considered likely
that vitamin K exerts its action after protein synthesis, at least after protein
synthesis sensu str'i,ctu i.e. after polypeptide synthesis (2, 20, 46). This makes
hypothesis c) unlikely and is in very good agreement with hypothesis d).
We first postulated the fourth hypothesis as a result of the above cited
experiments on PIVKA (17).
The recognition of the inhibiting protein PIVKA under conditions of
absence of vitamin K or administration of coumarol congeners, required a
postulate to explain why inhibition of the synthesis of one group of proteins
should go hand in hand with the appeara,nce of another one. A possible explana-
tion would be that the vitamin K dependent proteins are synthesized in a
multistep procedure. This would mean that one or more steps are necessa,ry
before the product of ribosomal polypeptide synthesis is converted into a
coagulation factor. Inhibition of a later step would then lead to the building up
of an intermediate product and this intermediate product would have all the
properties that PIVKA showed, i.e. it would be a protein that was very much
like the vitamin K dependent clotting factors, and be induced by the absence of
functional vitamin K. The polypeptide-precursor theory thus states that in the
normal genetically-determined way the parenchymatous liver cells synthesize
polypeptides which are direct precursors of the K dependent coagulation
factors. The synthesis of these polypeptides is thought to be independent of
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vitamin K. In a subsequent' step these polypeptides t'hen a're converted 
into the
functional coagulatioi factors. This second step is vitamin 
K depend.ent
(fig. 11).
Itisinaccord.ancewiththistheorythatlongtermtreatmentwithMarcou-
mar tends to cause a shift in the immunoelectrophoretic pattern of 
the plasma'
As can be seen f"o- figor" 12, t'he disappearance of precrpitation 
lines at
certain points of the imlunoelectropherJiram goes hand in 
hand with the
Feed back signal
@
Pre-prothrombinaemia + Hypoprothrombinaemia
FiE.l l .Schematicviewofthepost,ulatedmodeofgenerationofPlVl{A.Inthisgraph
- PIVKA is denoted' as 
"preprot'hronibitt" 
(from ref' 14)'
Feed back signal
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appea,rance of others. It is not claimed that the precipitation lines shown are
caused by the coagulation factors. Other proteins may as well be dependent on
vitamin K.
Fig. 12. Immunoelectrophoresis of plasma after prolonged Marcoumar intake.
The pathological plasma (top) is comparod to a normal plasma. Amido black, protein
staining.
On the nature of the second step we can but speculate, but as the factors
under discussion have been shown to be glycoproteins (29, 49,54), and as the
conversion protein + glycoprotein is known to occur after protein synthesis
(7, +l) it might be possible that this step, or part of it, is under influence of
vitamin K.
I will conclude this review with some brief remarks on the effect of vit-
amin K on the blood coagulation factor synthesis that has been inhibited by
Marcoumar (55).
It appears that any dose of vitamin Kr that causes an observable rise of the
Ievel of coagulation factors does so by a lswitch on< phenomenon. About two
hours after oral or intravenous administration of 1 or more mg of vitamin Kr
the level of all four clotting factors begins to rise. The velocity.of increase is
equal for all four clotting factors concerned from the 2nd. to the Sth. hour
after administration. After the Sth. hour each of the coagulation factors resumes
its own velocity of synthesis (fig. 13).
Only the duration of the effect is influenced by the dose of vitamin K1 given
(provided the dose exceeds 1 mg), the increase of the factors is not further
accelerated by intake of larger doses of vitamin Kr. This is consistent with the
view that vitamin Kr and Marcoumat compete for the same biologically active
site. The concentration at that site reached by 1 mg of vitamin K1 or rrore,
obviously represents an excess of vitamin Kt and thus completely negates the
effect of Marcoumar present.
The cause of the biphasic rea,ppearance is not well understood at the
moment. It may be related to the presence of polypeptide precursors of the
clotting factors in the liver cell, or to release phenomena from the cell.
The coagulation factor concentration after continued maximal stimulation
of the synthesis by vitamin K never exceeds the normal level, neither in healthy
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normal yolunteers not receiving Ma,rcoumar, nor in Yolunteers or patients undel
steady state anticoagulant treatment.
In conclusion, it can thus be said that coumarol congeners most proba-
bly depress the synthesis of certain plasma proteins among which the coa-
gotrtiott factors II, VII, IX and X by inhibiting a step in their synthesis
that occurs after polypeptide synthesis.
Fig' 18' schematic 
"**r#rjlJ""rilxir"ff;"r:t"lfrl:1?ililf dependent coaguration
Zusammenfassung : stiirungen iles Gerinnungsmechanismus ilurch
Vitamin -K -Antagonisten
Verabfolgt man eine ausreichend hohe Dosis eines Vitamin-K-Antagonist'en,
so verschwind.en die Gerinnungsfaktoren II, VII, IX und X aus dem Blut, und'
zwar mit der gleichen Geschwindigkeitsrate, mit der sie normalerweise elimi-
niert werd.en. Dieser ProzeB ist eine Reaktion erster Ordnung. Er liiBt sich
durch eine Konstante, d.ie biologische Halbwertszeit (BIIZ), kennzeichnen.
Durch die Dauereinnahme lron Cumarinderivaten kiinnen die Blutkonzentta'
tionen dieser vier Gerinnungsfaktoren gesenkt werden. Die hierzu erforder-
lichen Tagesdosen schwanken unter den einzelnen Individuen betriichtlich,
wii,hrend Vitamin K kaum individuelle Wirkungsunterschiede zeigt, sobald sich
die Gerinnungshemmung erst eingependelt hat.
Neben der senkung der Blutspiegel der genannten Gerinnungsfaktoren
fiihrt die Langzeitbehandlung mit Cumarind'erivaten zu einem anderen Phd'no-
men, das bislang unerkannt geblieben war. Es scheint, daB unter dem EinfluB
von Vitamin-K-Antagonisten ein neues Protein gebildet wird, das den Ge-
rinnungsfaktoren II, VII, IX und X hinsichtlich seiner physikochemischen
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Eigenschaften sehr iihnelt. Wir haben dieses Protein ))protein induced by vita-
min K absence( (PIVKA)genannt.
Auf dieses Protein wurden wir durch seine hemmende wirkung bei Gesamt-
gerinnungsbestimmungen aufmerksam, wie etwa bei der riThrombotest<-Be-
stimmung.
Der Angriffsort der kompetitiven r{emmung ist der Faktor X. vermutlich
ist PrvKA ein dem n'aktor X analoges substrat, das die rJmwandlung rron
Faktor X in n'aktor Xu durch Faktor Vrra hemmt und somit ein inaktives,
Prothrombjn-umwandelndes Enzym darstellt.
Die Gerinnungsfaktoren II, VII, IX und X und PIVKA scheinen gleicher
Herkunft zu sein. Wir stellten daher die folgende Hypothese auf: Die Vitamin-
K-abhringigen Gerinnungsfaktoren werden in einem Zwei-Phasen-ProzeB syn-
thetisiert. Die erste Phase ist die EiweiBsynthese. Das Produkt der ersten Phase
wird in einem Vitamin-K-abhei,ngigen Proze8 in einen biologisch wirksamen
Gerinnungsfaktor umgewandelt. Wird die zweite Phase gehemmt, so tritt dieses
rntermediEi,rprodukt, das normalerweise im kreisenden Blut nicht gefunden
wird, in die Blutbahn iiber. PIVKA wi.irde also das Produkt der ersten Stufe
sein. Beobachtungen an Patienten mit absolutem Vitamin-K-Mangel und mit
chronischer Hepatitis unterstiitzen diese Hypothese. Wir kcinnen uns der
Theorie nicht anschlieBen, daB Cumarinderivate an sich die EiweiBsynthese be-
einflussen. Vergleichende Untersuchungen von Dicumarol und Dinitrophenol
am Menschen und an der Ratte unterstiitzen unsere Ansicht. PrVKA hat sich
bisher noch nicht in reiner Form darstellen lassen. Das erzielte Produkt enthd,lt
noch Spuren der Gerinnungsfaktoren II, VII, IX und X. Dicumarol ruft Ver-
ti,nderungen im immunoelektrophoretischen Verhalten der Plasmaproteine her-
vor.
Bei einer Langzeitbehandlung mit Antikoagulantien bewirkt.Vitamin K,
da8 die Gerinnungsfaktoren erneut, im Blut erscheinen. Il;twa 2-B Std. nach
Verabfolgung von Vitamin K erscheinen alle 4 Gerinnungsfaktoren gleichzeitig
wieder. Ihre Synthese vollzieht sich unter normaler Geschwindigkeit, bis die
physiologischen Blutspiegel erreicht sind. Wir haben niemals ein rrUberschie-
Ben< iiber normale Konzentrationen hinaus beobachtet. Das von anderen
Autoren beschriebene UberschieBen lziBt sich wahrscheinlich d.ad.urch erklei,ren,
dafi diese den physiologischen Anstieg der Gerinnungsfaktoren vrr und rX
mit zunehmendem Alter au8er Acht qelassen hatten.
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